Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
TLC-6740 by OrsoBio for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval
TLC-6740 is under clinical development by OrsoBio and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to GlobalData,...
TLC-6740 by OrsoBio for Diabetes: Likelihood of Approval
TLC-6740 is under clinical development by OrsoBio and currently in Phase I for Diabetes. According to GlobalData, Phase I drugs...
TLC-6740 by OrsoBio for Obesity: Likelihood of Approval
TLC-6740 is under clinical development by OrsoBio and currently in Phase I for Obesity. According to GlobalData, Phase I drugs...
TLC-6740 by OrsoBio for Lipodystrophy (Lipoatrophy): Likelihood of Approval
TLC-6740 is under clinical development by OrsoBio and currently in Phase I for Lipodystrophy (Lipoatrophy). According to GlobalData, Phase I...
TLC-6740 by OrsoBio for Insulin Resistance: Likelihood of Approval
TLC-6740 is under clinical development by OrsoBio and currently in Phase I for Insulin Resistance. According to GlobalData, Phase I...
TLC-2716 by OrsoBio for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia): Likelihood of Approval
TLC-2716 is under clinical development by OrsoBio and currently in Phase I for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia). According to...
TLC-2716 by OrsoBio for Hypertriglyceridemia: Likelihood of Approval
TLC-2716 is under clinical development by OrsoBio and currently in Phase I for Hypertriglyceridemia. According to GlobalData, Phase I drugs...
TLC-2716 by OrsoBio for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval
TLC-2716 is under clinical development by OrsoBio and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to GlobalData,...